Efficacy of Autologous Outer-Root-Sheath Melanocytes Transplantation in the Treatment of Vitiligo

Inclusion Criteria: * Presence of symmetric lesions of vitiligo at the back of the hands with an extension \>5cm² * Vitiligo lasting at least one year at the backs of both hands * Stable vitiligo, defined as vitiligo that presents no evident evolution (appearance of new lesions or increase in the extension of lesions already present) for at least 6 months * Suspension for at least two months prior to the enrollment date of any systemic drug for vitiligo such as immunosuppressive treatment (cyclosporine, systemic steroids) or psoralen + ultraviolet A therapy, phototherapy with ultraviolet B, and of any anticoagulant drug * Suspension of topical medications for at least 15 days prior to the enrollment date Exclusion Criteria: * Presence of active vitiligo or Koebner phenomenon * Difference of more than 10% in the extension of symmetrical areas of vitiligo * Presence of systemic infections or infections localized to the tissues intended for transplantation * History of infections to the tissues intended for transplantation (herpes simplex, human papillomavirus infections, pityriasis versicolor, pityriasis alba) * Presence or history of malignancy * Chemotherapy or radiation therapy in progress * History of allergies or adverse reactions to local anesthetics * Presence of transmissible diseases (human immunodeficiency virus, hepatitis B and C, human T-lymphotropic virus type I and II, syphilis, cytomegalovirus, Creutzfeldt-Jacob, tuberculosis) * Women who are pregnant or intend to become pregnant during the study period (including breastfeeding women)